DOI: https://doi.org/10.24061/2413-0737.XXI.1.81.2017.42

Антагоністи мінералокортикоїдних рецепторів у лікуванні хронічної серцевої недостатності (огляд літератури)

S. V. Biletskyi, T. V. Kazantseva, O. A. Petrynych, V. V. Boyko

Анотація


В огляді літератури наводяться результати досліджень щодо застосування антагоністів мінералокортикоїдних рецепторів альдостерону спіронолактону і еплеренону в осіб із хронічною серцевою недостатністю.


Ключові слова


хронічна серцева недостатність; спіронолактон; еплеренон

Повний текст:

PDF

Посилання


Bagriy AE, Dyadyk AI, Shchukina EV. Antagonisty al'dosterona v lechenii bol'nykh s khronicheskoy serdechnoy nedostatochnost'yu i postinfarktnykh bol'nykh [Antagonists of aldosterone in the treatment of patients with chronic heart failure and postinfarction patients]. Serts. nedostatnist'. 2010;1:32-3. (in Russian).

Gilyarevskiy SR, Golshmid MV, Kuz'mina IM. Rol' antagonistov retseptorov al'dosterona v profilaktike i lechenii serdechno-sosudistykh i pochechnykh zabolevaniy: real'nost' i perspektivy [The role of antagonists of aldosterone receptors in the prevention and treatment of cardiovascular and renal diseases: reality and prospects]. Rus. med. zh. 2014;23:1689-693. (in Russian).

Dzyak GV, Vasil'eva LI. Blokada renin-angiotenzin-al'dosteronovoy sistemy kak kraeugol'nyy kamen' lecheniya khronicheskoy serdechnoy nedostatochnosti [Blockade of the renin-angiotensin-aldosterone system as a cornerstone of the treatment of chronic heart failure]. Serts. nedostatnist'. 2009;1:18-30. (in Russian).

Zharinov OI. Evoliutsiia rekomendatsii z medykamentoznoho ta khirurhichnoho likuvannia sertsevoi nedostatnosti [Evolution of recommendations for medical and surgical treatment of heart failure]. Med. svitu. 2012;ХХІІІ(41):5-10. (in Ukrainian).

Zharinov OI. Spironolakton u suchasnii kardiolohichnii praktytsi: vidomi ta novi fakty [Spironolactone in modern cardiology practice: known and new facts]. Zdorov’ia Ukrainy. 2016;1:31-3. (in Ukrainian).

Kozhukhov SN, Parkhomenko AN. Nauchnye dokazatel'stva effektivnosti eplerenona u bol'nykh s disfunktsiey levogo zheludochka: ot infarkta miokarda k serdechnoy nedostatochnosti [Scientific evidence of the efficacy of eplerenone in patients with left ventricular dysfunction: from myocardial infarction to heart failure]. Ukr. kardiol. zh. 2015;1:105-11. (in Russian).

Kuriata OV, Kushnir IuS. Masa tila ta rivni al'dosteronu, leptynu u khvorykh na khronichnu sertsevu nedostatnist' zi zberezhenoiu fraktsiieiu vykydu [Body weight and aldosterone levels, leptin in patients with chronic heart failure with a preserved ejection fraction]. Suchas. med. tekhnolohii. 2014;1:12-6. (in Ukrainian).

Voronkov LH, Amosova KM, Bahrii AE. Rekomendatsii z diahnostyky ta likuvannia khronichnoi sertsevoi nedostatnosti (2012) [Recommendations for the diagnosis and treatment of chronic heart failure (2012)]. Access mode: http://ukrsn.com/rekomendatsii-z- diahnostyky ta likuva- 371. (in Ukrainian).

Rekomendatsii Ukrains'koi asotsiatsii kardiolohiv z diahnostyky, likuvannia ta profilaktyky khronichnoi sertsevoi nedostatnosti u doroslykh (skorochenyi variant) [Recommendations of the Ukrainian Association of Cardiologists for the Diagnosis, Treatment and Prevention of Chronic Heart Failure in Adults (short version]. Skhidnoievrop. zh. vnutr. ta sim. medytsyny. 2015;1:65-71. (in Ukrainian).

Mareev VYu, Skvortsov AA, Chelmakina SM. Sposobny li ingibitory APF effektivno kontrolirovat' aktivnost' renin-angiotenzin-al'dosteronovoy sistemy pri dlitel'nom lechenii khronicheskoy serdechnoy nedostatochnosti? [Are ACE inhibitors effective in controlling the activity of the renin-angiotensin-aldosterone system during long-term treatment of chronic heart failure?]. Kardiologiya. 1999;2:27-34. (in Russian).

Taschuk VK, Polians'ka OS, Hulaha OI. Novipidkhody do diahnostyky ta likuvannia sertsevoi nedostatnosti [New approaches to the diagnosis and treatment of heart failure]. Buk. med. visnyk. 2014;18(2):159-61. (in Ukrainian).

Cohn JN, Johnson G, Ziesche S. A comparison of enalapril with hydralasine – isosorbide dinitrate in the treatment of chronic congestive heart failure. New Engl. J. Med. 1991;325(5):303-10.

Mano A, Tatsumi T, Shiraishi J. Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways. Circulation. 2004;110(3):317-23.

Rocha R, Rudolph AE, Frierdich GE. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart. Circ. Physiol. 2002;283(5):H1802-810.

Guichard JL, ClarkD, Calhoun DA. Aldosterone receptor antagonists: current perspectives and therapies. Vasc. Health Risk. Manag. 2013;9:321-31.

Oberleithner H, Riethmuller C, Ludwig T. Aldosterone remodels human endothelium. Acta Physiol. 2006;187(1-2):305-12.

Rude MK, Duhaney, Kuster G. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension. 2005;46(3):555-61.

Fiebeler A, Muller DN, Shagdarsuren E. Aldosterone, mineralocorticoid receptors, and vascular inflammation. Curr. Opin. Nephrol. Hypertens. 2007;16(3):134-42.

Cohn JN, Colucci W. Cardiovascular effects of aldosterone and postacute myocardial infarction pathophysiology. Am. J. Cardiol. 2006;97(10): 4-12.

Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circul. 2005;111(23):3025-33.

DeMello WC. Beneficial effect of eplerenone on cardiac remodeling and electrical properties of the failing heart. J. Renin-Angiotensin-AldosteronSystem. 2006;7(1):40-6.

Dhillon S. Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms. Drugs. 2013;73(13):1451-462.

Jorde UP, Vittorio T, Katz SD. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation. 2002;106(9):1055-57.

Pitt B, Bakris G, Ruilope LM. EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008;118(16):1643-650.

Zannad F, McMurray JJ, Krum H. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N. Engl. J. Med. 2011;364(1):11-21.

Pitt B, Remme W, Zannad F. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N. Engl. J. Med. 2003;348(14):1309-321.

McMurray JJ, Adamopoulos S, Anker SD. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 2012;14(8):803-69.

Beygui F, Collet JP, Benoliel JJ. High Plasma Aldosterone Levelson Admission Are Associated With Deathin Patients Presenting With Acute STElevation Myocardial Infarction. Circulation. 2006;114(24):2604-610.

Menuet Le D, Munier M, Meduri G. Mineralocorticoid receptor over expressi on in embryon ics temcell-derived cardiomyocytes in creases their beating frequency. Cardiovasc. Res. 2010;87(3):467-75.

Pitt B. «Escape» of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc. Drugs Ther. 1995;9(1):145-49.

Yasue H, Mizuno Y, Harada E. Renin-angiotensin-aldosterone system and natriuretic peptide system – reference to cardiovascular disease. Nippon Rinsho. 2004;62(9):164-69.

Eschalier R, McMurray JJ, Swedberg K. Safety and efficacy of eplerenone in patients at high-risk for hyperkalemia and/or worsening renal function: analyses of EMPHASIS-HF study subgroups. J. Am. Coll. Cardiol. 2013;62(17):1585-593.

Iqbal J, Parviz Y, Pitt B. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Eur. J. Heart Fail. 2014;16(2):143-50.

Shroff SC, Ryu K, Martovitz NL. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J. Cardiovasc. Electrophysiol. 2006;17(5):534-41.

Shah KB, Rao K, Sawyer R. The Adequacy of Laboratory Monitoring in Patients Treated With Spironolactone for Congestive Heart Failure. J. Am. Coll. Cardiol. 2005;46(5):845-49.

The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl. J. Med. 1987;316(23):1429-435.

Cohn JN, Johnson G, Lieshe S. The SOLVD Investigators: Effect of the angiotensinconverting enzyme inhibitor enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. New Engl. J. Med. 1991;325(5):293-2.

Weber KT. Aldosterone in congestive heart failure. N. Engl. J. Med. 2001;345(23):1689-697.


Пристатейна бібліографія ГОСТ






Copyright (c) 2018 S. V. Biletskyi, T. V. Kazantseva, O. A. Petrynych, V. V. Boyko

Технічний редактор журналу, к.мед.н. М. Степанченко, 2015-2019